Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction
DOI:
https://doi.org/10.61919/jhrr.v4i3.1368Keywords:
Percutaneous coronary intervention, , Ischemic Left Ventricular Dysfunction, Ejection FractionAbstract
Background:
Ischemic left ventricular (LV) dysfunction, characterized by reduced ejection fraction due to coronary artery disease (CAD), is associated with high morbidity and mortality. Percutaneous coronary intervention (PCI) aims to restore blood flow in ischemic myocardium, potentially improving outcomes in this high-risk population.
Objective:
To evaluate the effects and safety of PCI in managing patients with ischemic LV dysfunction.
Methods:
This prospective single-center study was conducted at the Department of Cardiology, PIMS, Islamabad, from March 1, 2024, to July 31, 2024. A total of 225 patients with ischemic LV dysfunction (EF < 40%) and significant CAD were enrolled and divided into PCI (n = 123) and medical therapy (MT) (n = 102) groups. Exclusion criteria included non-ischemic cardiomyopathy, severe comorbidities, and recent myocardial infarction. Primary outcomes were EF improvement and MACE rates. Secondary outcomes included NYHA class improvement and quality of life assessed by the Minnesota Living with Heart Failure Questionnaire (MLHFQ).
Results:
The PCI group showed a significant EF improvement (8.1% vs. 3.2%, p < 0.01) and lower MACE rates (13.8% vs. 24.5%, p = 0.03). Quality of life improved more in the PCI group (MLHFQ score reduction, p < 0.01).
Conclusion:
PCI significantly improves LV function, reduces MACE, and enhances quality of life in patients with ischemic LV dysfunction compared to MT.
Downloads
References
Gheorghiade M, Bonow RO. Chronic Heart Failure in the United States: A Manifestation of Coronary Artery Disease. Circulation. 1998;97(3):282-289. doi:10.1161/01.CIR.97.3.282
Heidenreich PA, Trogdon JG. Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement from the American Heart Association. Circulation. 2011;123(8):933-944. doi:10.1161/CIR.0b013e31820a55f5
Myerburg RJ, Castellanos A. Cardiac Arrest and Sudden Cardiac Death. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology: From Cell to Bedside. 5th ed. Elsevier; 2008. doi:10.1016/B978-1-4160-4852-9.00112-1
Velazquez EJ, Lee KL, Jones RH. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. N Engl J Med. 2011;364(17):1607-1616. doi:10.1056/NEJMoa1100356
Di Carli MF, Hachamovitch R, Rozanski A. Prognostic Value of Myocardial Perfusion Imaging in Patients with Coronary Artery Disease and Left Ventricular Dysfunction. J Am Coll Cardiol. 2000;36(6):1861-1867. doi:10.1016/S0735-1097(00)00932-8
Levine GN, Bates ER, Blankenship JC. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. J Am Coll Cardiol. 2011;58(24). doi:10.1016/j.jacc.2011.08.007
Stone GW, Grines CL. Primary Percutaneous Coronary Intervention Compared with Thrombolysis. N Engl J Med. 2001;344(13):936-946. doi:10.1056/NEJM200103293441301
Al-Lamee R, Thompson D, Dehbi HM. Percutaneous Coronary Intervention in Stable Angina (ORBITA): A Double-Blind, Randomised Controlled Trial. Lancet. 2018;391(10115):31-40. doi:10.1016/S0140-6736(17)32714-9
Bangalore S, Maron DJ, Stone GW. Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials. Circulation. 2020;142(9):841-857. doi:10.1161/CIRCULATIONAHA.120.048194
Packer M. The Role of Percutaneous Coronary Intervention in Managing Stable Ischemic Heart Disease. J Am Coll Cardiol. 2019;73(7):964-966. doi:10.1016/j.jacc.2018.12.029
Baks T, van Geuns RJ, Duncker DJ, Cademartiri F, Borgers M, Krestin GP, Serruys PW, de Feyter PJ. Effects of Percutaneous Coronary Intervention on Global and Regional Left Ventricular Function in Patients with Chronic Ischemic Left Ventricular Dysfunction. J Am Coll Cardiol. 2006;47(2):302-308. doi:10.1016/j.jacc.2005.08.065
Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, Bonow RO, Doenst T, Petrie MC, Oh JK, Moore WJ, Desvigne-Nickens P, Spertus JA, She L, O’Connor CM, Sopko G, Rouleau JL, STICHES Investigators. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med. 2016;374(16):1511-1520. doi:10.1056/NEJMoa1602001
Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Weintraub WS. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl J Med. 2007;356(15):1503-1516. doi:10.1056/NEJMoa070829
De Bruyne B, Pijls NHJ, Kalesan B, Barbato E, Tonino PAL, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engstrøm T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Fearon WF. Fractional Flow Reserve-Guided PCI Versus Medical Therapy in Stable Coronary Disease. N Engl J Med. 2012;367(11):991-1001. doi:10.1056/NEJMoa1205361
Rogers WJ, Johnstone DE, Yusuf S, Carroll CG. Quality of Life Among Patients Randomized to Receive Medical Therapy or Coronary Artery Bypass Graft Surgery: 5-Year Follow-Up in the Coronary Artery Surgery Study (CASS). Circulation. 1994;90(5 Pt 2). doi:10.1161/01.CIR.90.5.II-118
Velazquez EJ, Lee KL, Jones RH, et al. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. N Engl J Med. 2011;364(17):1607-1616. doi:10.1056/NEJMoa1100356
Packer M. The Role of Percutaneous Coronary Intervention in Managing Stable Ischemic Heart Disease. J Am Coll Cardiol. 2019;73(7):964-966. doi:10.1016/j.jacc.2018.12.029
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Muhammad Sibghatullah, Akhtar Bandeshah, Iqra Batool
This work is licensed under a Creative Commons Attribution 4.0 International License.
